StockNews.com Begins Coverage on Titan Pharmaceuticals (NASDAQ:TTNP)

by · The Markets Daily

StockNews.com initiated coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Free Report) in a research report released on Thursday morning. The firm issued a sell rating on the specialty pharmaceutical company’s stock.

Titan Pharmaceuticals Trading Down 2.8 %

Titan Pharmaceuticals stock opened at $3.85 on Thursday. Titan Pharmaceuticals has a 1 year low of $3.63 and a 1 year high of $14.80. The firm’s 50 day moving average price is $5.54 and its 200-day moving average price is $6.01.

Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) last released its quarterly earnings data on Thursday, August 15th. The specialty pharmaceutical company reported ($2.29) earnings per share (EPS) for the quarter.

Titan Pharmaceuticals Company Profile

(Get Free Report)

Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.

Read More